RTV: Clinical Trials

33 completed, 1 recruiting, 1 terminated. 13 Phase 3, 10 Phase 1, 10 Phase 2, 2 Not applicable, 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 3	13	Completed 13
Phase 1	10	Completed 9, Recruiting 1
Phase 2	10	Completed 9, Terminated 1
Not applicable	2	Completed 2
Phase 4	1	Completed 1

Follow RTV: new trials by email Literature Review of RTV trials Research Report on RTV

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
STARLITE for Unresectable High-Grade Gliomas Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine - High Grade Glioma	Phase 1	Recruiting	University of Miami	24	2025-04-15	2026-06-25
GLS4/RTV and TAF Drug-drug Interaction GLS4, RTV, TAF - Chronic Hepatitis B	Phase 1	Completed	Sunshine Lake Pharma Co., Ltd.	28	2021-01-10	2022-05-26
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection GLS4, RTV, ETV - Chronic HBV Infection	Phase 2	Completed	Sunshine Lake Pharma Co., Ltd.	250	2019-02-28	2024-06-21
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus	Phase 3	Completed	Eiger BioPharmaceuticals	407	2018-12-01	2023-04-14
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects GLS4, RTV, ETV - Chronic Hepatitis B	Phase 1	Completed	Sunshine Lake Pharma Co., Ltd.	56	2018-06-26	2019-10-09
Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus GS-9131, BIC, TAF - HIV-1-infection	Phase 2	Terminated	Gilead Sciences	21	2018-04-03	2021-01-05
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules GLS4, RTV - Chronic Hepatitis B	Phase 2	Completed	Sunshine Lake Pharma Co., Ltd.	20	2017-07-26	2020-07-23
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China Ravidasvir, Danoprevir, Ritonavir - Healthy	Phase 1	Completed	Ascletis Pharmaceuticals Co., Ltd.	18	2016-07-15	2018-06-29
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women E/C/F/TAF, E/C/F/TDF, ATV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	472	2016-02-19	2020-03-04
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults RTV, ATV, DRV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	578	2015-11-20	2020-12-29
Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China Danoprevir, Ritonavir, Placebo - Healthy	Phase 1	Completed	Ascletis Pharmaceuticals Co., Ltd.	18	2015-10-01	2017-01-13
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults STB, TVD, ATR - HIV-1 Infection	Phase 4	Completed	Gilead Sciences	72	2014-12-15	2018-01-03
Lonafarnib With and Without Ritonavir in HDV (LOWR-1) lonafarnib, peginterferon alfa-2a, ritonavir - Chronic Hepatitis D Infection	Phase 2	Completed	EIT Pharma, Inc.	21	2014-11-01	2026-09-25
Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study atazanavir 300mg boosted with ritonavir 50 mg - HIV Infection	Phase 1	Completed	Ottawa Hospital Research Institute	12	2014-01-01	2015-09-22
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) IDX719, Simeprevir, TMC647055 - Hepatitis C, Chronic	Phase 1	Completed	Merck Sharp & Dohme LLC	34	2013-05-01	2016-01-26
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF - HIV, HIV Infections	Phase 3	Completed	Gilead Sciences	1443	2013-03-27	2021-04-13
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women E/C/F/TDF, ATV, RTV - Acquired Immunodeficiency Syndrome, HIV Infections	Phase 3	Completed	Gilead Sciences	583	2012-10-24	2019-09-20
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen Darunavir, Ritonavir, Tenofovir disoproxil fumarate - HIV-1 Infection	Phase 2	Completed	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	262	2012-01-17	2024-10-15
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients PI, RTV, FTC/TDF - Acquired Immunodeficiency Syndrome, HIV Infections	Phase 3	Completed	Gilead Sciences	438	2011-11-01	2016-06-08
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF FTC/RPV/TDF, PI, RTV - HIV-1 Infection	Phase 3	Completed	Gilead Sciences	482	2010-11-01	2015-12-04

Showing 20 of 35. Sign in to see all of them.

Conditions studied

HIV Infections (14)  ·  Acquired Immunodeficiency Syndrome (5)  ·  Hepatitis B, Chronic (3)  ·  Glioma (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Hepatitis D (1)  ·  Tuberculosis (1)

Sponsors

Gilead Sciences (11)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Sunshine Lake Pharma Co., Ltd. (4)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3)  ·  Tibotec Pharmaceuticals, Ireland (3)  ·  Ascletis Pharmaceuticals Co., Ltd. (2)  ·  Boehringer Ingelheim (1)  ·  Bristol-Myers Squibb (1)  ·  EIT Pharma, Inc. (1)  ·  Eiger BioPharmaceuticals (1)  ·  GlaxoSmithKline (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Ottawa Hospital Research Institute (1)  ·  University of Miami (1)

Countries

United States (21)  ·  Puerto Rico (15)  ·  United Kingdom (12)  ·  France (11)  ·  Belgium (10)  ·  Spain (10)  ·  Canada (9)  ·  Germany (9)  ·  Italy (8)  ·  Austria (7)  ·  Australia (6)  ·  Dominican Republic (6)  ·  Thailand (6)  ·  Portugal (5)  ·  Brazil (4)

Top investigators

Huoling Tang, PhD (2)  ·  Ashish Shah, MD (1)  ·  Babafemi Taiwo, MBBS, MD (1)  ·  Brian Conway (1)  ·  Cihan Yurdaydin, MD (1)  ·  David W. Haas, MD (1)  ·  Eric Daar, MD (1)  ·  Huyen Cao, MD (1)  ·  Igho Ofotokun, MD (1)  ·  Jeffrey L. Lennox, MD (1)  ·  Jennifer King, PharmD (1)  ·  John Flaherty, PharmD (1)

Results publications

PMID 33901188, PMID 36912172, PMID 17576825, PMID 19952143, PMID 20001856, PMID 21148235, PMID 21320923, PMID 21606537, PMID 21690627, PMID 21732894, PMID 21811136, PMID 22121190, PMID 23148287, PMID 23204164, PMID 23532097, PMID 23558157, PMID 24253247, PMID 24384588, PMID 24637543, PMID 24872136, PMID 24908550, PMID 24908551, PMID 24979445, PMID 25285539, PMID 25767256, PMID 25904376, PMID 26009829, PMID 26060295, PMID 26181707, PMID 26286337, PMID 26538525, PMID 26797215, PMID 27562742, PMID 27774892, PMID 28259777, PMID 28555519, PMID 29368537, PMID 29925490, PMID 30642925, PMID 30932951, PMID 31303140, PMID 31430369, PMID 31609930, PMID 31826005, PMID 32829410, PMID 33870433, PMID 35179037, PMID 37407002, PMID 38160309, PMID 39988055

NIH funding

U01AI068636 (3), 2008 (1), 2009 (1), 2014 (1), 2015 (1)